124 related articles for article (PubMed ID: 30657372)
21. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study.
Lin JF; Muñiz K; Sukumvanich P; Gehrig P; Beriwal S; Kelley JL; Edwards RP; Olawaiye AB
BJOG; 2016 Oct; 123(11):1846-52. PubMed ID: 26537059
[TBL] [Abstract][Full Text] [Related]
22. Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: Analysis of the National Cancer Data Base.
Haque W; Verma V; Fakhreddine M; Hatch S; Butler EB; Teh BS
Gynecol Oncol; 2017 Jan; 144(1):28-33. PubMed ID: 27784533
[TBL] [Abstract][Full Text] [Related]
23. Postoperative Chemoradiation Therapy in High-Risk Cervical Cancer: Re-evaluating the Findings of Gynecologic Oncology Group Study 109 in a Large, Population-Based Cohort.
Trifiletti DM; Swisher-McClure S; Showalter TN; Hegarty SE; Grover S
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1032-44. PubMed ID: 26581141
[TBL] [Abstract][Full Text] [Related]
24. Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study.
Rajagopalan MS; Xu KM; Lin JF; Sukumvanich P; Krivak TC; Beriwal S
Gynecol Oncol; 2014 Dec; 135(3):495-502. PubMed ID: 25281493
[TBL] [Abstract][Full Text] [Related]
25. Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder.
Fischer-Valuck BW; Rao YJ; Henke LE; Rudra S; Hui C; Baumann BC; Gay HA; Michalski JM
Eur Urol Focus; 2018 Dec; 4(6):900-906. PubMed ID: 28919521
[TBL] [Abstract][Full Text] [Related]
26. Pattern of Care, Health Care Disparities, and Their Impact on Survival Outcomes in Stage IVB Cervical Cancer: A Nationwide Retrospective Cohort Study.
Jalloul RJ; Sharma S; Tung CS; O'Donnell B; Ludwig M
Int J Gynecol Cancer; 2018 Jun; 28(5):1003-1012. PubMed ID: 29757872
[TBL] [Abstract][Full Text] [Related]
27. Patterns of Recurrence in Node-Positive Cervical Cancer Patients Treated With Contemporary Chemoradiation and Dose Escalation: A Multi-Institutional Study.
Sethi R; Mayadev J; Sethi S; Rash D; Chen LM; Brooks R; Ueda S; Hsu IC
Pract Radiat Oncol; 2019 Mar; 9(2):e180-e186. PubMed ID: 30342181
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
29. Addition of Definitive Radiotherapy to Chemotherapy in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer.
Verma V; Allen PK; Simone CB; Gay HA; Lin SH
J Natl Compr Canc Netw; 2017 Nov; 15(11):1383-1391. PubMed ID: 29118230
[No Abstract] [Full Text] [Related]
30. Clinical Role of Adjuvant Chemotherapy after Radical Hysterectomy for FIGO Stage IB-IIA Cervical Cancer: Comparison with Adjuvant RT/CCRT Using Inverse-Probability-of-Treatment Weighting.
Jung PS; Kim DY; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
PLoS One; 2015; 10(7):e0132298. PubMed ID: 26176626
[TBL] [Abstract][Full Text] [Related]
31. Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base.
Lester-Coll NH; Park HS; Rutter CE; Corso CD; Young MR; Ratner ES; Litkouhi B; Decker RH; Yu JB; Damast S
Gynecol Oncol; 2016 Jul; 142(1):54-61. PubMed ID: 27151429
[TBL] [Abstract][Full Text] [Related]
32. The impact of adjuvant vaginal brachytherapy in women with Stage II uterine endometrioid carcinoma: Results of a National Cancer Database analysis.
Lee JK; Ghanem AI; Modh A; Burmeister C; Mahmoud O; Maxwell GL; Elshaikh MA
Brachytherapy; 2018; 17(2):319-325. PubMed ID: 29174935
[TBL] [Abstract][Full Text] [Related]
33. Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation.
Ho JC; Allen PK; Bhosale PR; Rauch GM; Fuller CD; Mohamed AS; Frumovitz M; Jhingran A; Klopp AH
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):546-553. PubMed ID: 28011045
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.
Ecker BL; McMillan MT; Datta J; Lee MK; Karakousis GC; Vollmer CM; Drebin JA; Fraker DL; Roses RE
Cancer; 2017 May; 123(6):967-976. PubMed ID: 28263387
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Body Radiation Therapy, Intensity-Modulated Radiation Therapy, and Brachytherapy Boost Modalities in Invasive Cervical Cancer: A Study of the National Cancer Data Base.
OʼDonnell B; Shiao JC; Pezzi TA; Waheed N; Sharma S; Bonnen MD; Ludwig MS
Int J Gynecol Cancer; 2018 Mar; 28(3):563-574. PubMed ID: 29324547
[TBL] [Abstract][Full Text] [Related]
36. Cervical cancer care in rural Virginia: The impact of distance from an academic medical center on outcomes & the role of non-specialized radiation centers.
Rauh LA; Saks EJ; Nakad-Rodriguez D; Showalter TN; Duska LR
Gynecol Oncol; 2018 Aug; 150(2):338-342. PubMed ID: 29935911
[TBL] [Abstract][Full Text] [Related]
37. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
[No Abstract] [Full Text] [Related]
38. Open versus laparoscopic pelvic lymph node dissection in early stage cervical cancer: no difference in surgical or disease outcome.
van de Lande J; von Mensdorff-Pouilly S; Lettinga RG; Piek JM; Verheijen RH
Int J Gynecol Cancer; 2012 Jan; 22(1):107-14. PubMed ID: 21857347
[TBL] [Abstract][Full Text] [Related]
39. Primary Versus Preoperative Radiation for Locally Advanced Vulvar Cancer.
Natesan D; Hong JC; Foote J; Sosa JA; Havrilesky L; Chino J
Int J Gynecol Cancer; 2017 May; 27(4):794-804. PubMed ID: 28333840
[TBL] [Abstract][Full Text] [Related]
40. Impact of facility volume on therapy and survival for locally advanced cervical cancer.
Lin JF; Berger JL; Krivak TC; Beriwal S; Chan JK; Sukumvanich P; Monk BJ; Richard SD
Gynecol Oncol; 2014 Feb; 132(2):416-22. PubMed ID: 24333361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
